DOI: 10.1055/s-00000069

Seminars in Liver Disease

References


BRISK-FL study with investigational compound brivanib in hepatocellular carcinoma does not meet overall survival primary endpoint [press release].
Princeton, NJ: Bristol-Myers Squibb; July 19, 2012. Available at:
http://www.reuters.com/article/2012/07/19/idUS218420+19-Jul-2012+BW20120719 . Accessed July 20, 2012

Download Bibliographical Data

Search in: